Bulk Manufacturer of Controlled Substances Application: Johnson Matthey Pharmaceutical Materials, Inc., 23069 [2017-10233]
Download as PDF
<![CDATA[
23069
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
Controlled substance
Drug code
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .......................................................................................................................
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ......................................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..................................................................
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ........................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ..............................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .......................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Desomorphine .................................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Noroxymorphone .............................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10231 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Johnson
Matthey Pharmaceutical Materials, Inc.
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before July 18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of application.
7019
7118
7122
7144
7173
7315
7348
7400
7404
7405
7535
7540
9055
9634
7471
9273
9668
9740
9780
9801
Drug code
Amphetamine ...................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
September 26, 2016, Johnson Matthey
Pharmaceutical Materials, Inc.,
Pharmaceutical Service, 25 Patton Road,
Devens, Massachusetts 01434 applied to
be registered as a bulk manufacturer of
the following basic classes controlled
substances:
Controlled substance
The company plans to utilize this
facility to manufacture small quantities
of the listed controlled substances in
bulk for distribution to its customers as
well as to conduct analytical testing in
support of the company’s primary
manufacturing facility in West Deptford,
New Jersey.
Schedule
1100
1724
7379
9193
9737
9739
9740
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
[FR Doc. 2017–10233 Filed 5–18–17; 8:45 am]
Schedule
[Docket No. DEA–392]
Drug Enforcement Administration
BILLING CODE 4410–09–P
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
DATES:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Page 23069]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10233]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Johnson
Matthey Pharmaceutical Materials, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before July 18, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
September 26, 2016, Johnson Matthey Pharmaceutical Materials, Inc.,
Pharmaceutical Service, 25 Patton Road, Devens, Massachusetts 01434
applied to be registered as a bulk manufacturer of the following basic
classes controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Amphetamine........................ 1100 II
Methylphenidate.................... 1724 II
Nabilone........................... 7379 II
Hydrocodone........................ 9193 II
Alfentanil......................... 9737 II
Remifentanil....................... 9739 II
Sufentanil......................... 9740 II
------------------------------------------------------------------------
The company plans to utilize this facility to manufacture small
quantities of the listed controlled substances in bulk for distribution
to its customers as well as to conduct analytical testing in support of
the company's primary manufacturing facility in West Deptford, New
Jersey.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-10233 Filed 5-18-17; 8:45 am]
BILLING CODE 4410-09-P
